title: Implication of circulating omentin-1 level on the arterial stiffening in type 2 diabetes mellitus.
abstract: Omentin-1 is an adipokine implicated in diabetes, inflammation, and cardiovascular disease. However, no prospective studies have examined the impact of circulating omentin-1 levels on arterial stiffening in patients with type 2 diabetes mellitus. For the purpose of this study, we recruited 120 patients with type 2 diabetes mellitus and measured serum omentin-1, adiponectin, and high-sensitivity C-reactive protein levels as well as other cardiovascular risk factors. Arterial stiffness was assessed by brachial ankle pulse wave velocity (baPWV). An increase in the level of circulating omentin-1 over a period of 1 year was positively correlated with changes in levels of HbA1c and serum adiponectin as well as baPWV. Subjects with higher baseline serum omentin-1 levels tended to have a reduced arterial stiffness after 1 year (P for linear trend = 0.03). In the group with increased baPWV after 1 year, the magnitude of increase of circulating omentin-1 levels was significantly higher than in the group with a lower baPWV after 1 year (134.3 [16.6, 277.1] ng/mL vs. 15.9 [-67.6, 145.7] ng/mL, P < 0.01). Multiple stepwise logistic regression analysis revealed that an increase in systolic blood pressure and an increase in serum omentin-1 level were independently correlated with arterial stiffening, even after adjusting for other cardiovascular risk factors and medication history. Baseline serum omentin-1 levels can predict arterial stiffness changes occurring within a year. Furthermore, changes in serum omentin-1 levels after a year can function as independent markers of arterial stiffening in patients with type 2 diabetes mellitus.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea.
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Yoo
authors.forename: Soon Young
authors.initials: SY
authors.lastname: Hwang
authors.forename: Ho Cheol
authors.initials: HC
authors.lastname: Hong
authors.forename: Hae Yoon
authors.initials: HY
authors.lastname: Choi
authors.forename: Sae Jeong
authors.initials: SJ
authors.lastname: Yang
authors.forename: Kwan Woo
authors.initials: KW
authors.lastname: Lee
authors.forename: Moon Suk
authors.initials: MS
authors.lastname: Nam
authors.forename: Yong Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Jeong Taek
authors.initials: JT
authors.lastname: Woo
authors.forename: Young Seol
authors.initials: YS
authors.lastname: Kim
authors.forename: Kyung Mook
authors.initials: KM
authors.lastname: Choi
authors.forename: Sei Hyun
authors.initials: SH
authors.lastname: Baik
mesh_terms: D052242:Adiponectin / Q000097:blood; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein; D016207:Cytokines / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000097:blood / Q000503:physiopathology*; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood; D006801:Humans; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D059289:Vascular Stiffness / Q000502:physiology*
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D037102:Lectins; D002097:C-Reactive Protein